MAPK1 and central nervous system cancer: PLX4720 treatment increased EGFR phosphorylation, and also activated downstream effectors MEK and ERK, in all three BRAFV600E glioma cell lines, as early as 1 hour post-PLX4720 treatment (Figure 4A).